FY2024 EPS Estimates for AxoGen Reduced by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Cantor Fitzgerald cut their FY2024 earnings per share estimates for shares of AxoGen in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now anticipates that the medical equipment provider will earn ($0.58) per share for the year, down from their previous estimate of ($0.28). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Cantor Fitzgerald also issued estimates for AxoGen’s FY2025 earnings at $0.19 EPS.

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.

AxoGen Stock Performance

AXGN opened at $18.89 on Thursday. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $15.40 and a two-hundred day simple moving average of $13.30. AxoGen has a 12-month low of $5.55 and a 12-month high of $19.03.

Institutional Investors Weigh In On AxoGen

Large investors have recently added to or reduced their stakes in the stock. Quest Partners LLC lifted its holdings in shares of AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 2,076 shares during the period. R Squared Ltd purchased a new stake in AxoGen during the fourth quarter valued at $30,000. nVerses Capital LLC bought a new position in AxoGen in the third quarter valued at about $56,000. Oppenheimer & Co. Inc. purchased a new position in AxoGen in the third quarter worth about $156,000. Finally, Quantbot Technologies LP bought a new stake in shares of AxoGen during the 3rd quarter valued at about $165,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.